Abstract Number: 519 • ACR/ARP Annual Meeting 2019
Efficacy of Biosimilar Candidate ABP 710 in a Phase 3 Study in Subjects with Moderate to Severe RA: Additional Analysis Focusing on the ACR Individual Components
Background/Purpose: ABP 710 is being developed as a biosimilar to infliximab. Both ABP 710 and infliximab reference product (RP) inhibit tumor necrosis factor-alpha. Following demonstration…Abstract Number: 2192 • ACR/ARP Annual Meeting 2019
Stabilization of Patellar Bone-Shape Correlates Significantly with Reduced Knee Pain Frequency After IA TPX-100 in Subjects with Bilateral Patellofemoral OA
Background/Purpose: Based on data from the Osteoarthritis Initiative (OAI), MRI-based analyses of bone shape changes in the knee predict symptomatic and radiographic progression of knee…Abstract Number: 3249 • ACR/ARHP Annual Meeting 2015
Pooled Efficacy and Safety from Phase 3 Controlled Studies of Tanezumab in Patients with Osteoarthritis
Background/Purpose: Tanezumab (TNZ) significantly reduces pain and improves physical function and Patient's Global Assessment (PGA) in patients with chronic pain. From June 2010 to August…
ACR Meeting Abstracts